Clinical Advances in Hematology & Oncology (CAH&O), is a monthly peer-reviewed journal reaching nearly 26,000 hematology and oncology clinicians. CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of today’s top thought leaders in hematology & oncology–including thought leader-driven feature-length review articles, monthly columns comprised of engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, and drug development. CAH&O also publishes industry-supported Meeting Highlights, Clinical Roundtable Monographs, and Clinical Review Supplements. Both the journal and all affiliated supplements are included in the National Library of Medicine’s PubMed/MEDLINE index as well as EMBASE.
The May issue is available on our website
http://www.hematologyandoncology.net/current-issue/
H&O Which immunotherapy agents have been approved for use in colorectal cancer (CRC) with mismatch repair deficiency (MMR-D)? MO We have a choice of 3 […]
The March issue of Clinical Advances in Hematology & Oncology is available on our website. http://www.hematologyandoncology.net/
The February issue is available on our website
H&O How does the National Institute for Health and Care Excellence assign value to drugs and select the ones that will be covered by the […]
The January issue of Clinical Advances in Hematology & Oncology is available on our site. http://www.hematologyandoncology.net/
H&O How is erythrocytosis defined? JP Erythrocytosis is the presence of too many red blood cells. Several different parameters are used to diagnose erythrocytosis in […]
The November issue is now available on our site
H&O How common is human epidermal growth factor receptor 2 (HER2) amplification in metastatic colorectal cancer (mCRC)? KR HER2 amplification is found in approximately 3% […]
The October issue of Clinical Advances in Hematology & Oncology is available on our website
H&O What are some ethical concerns regarding the typical design of clinical trials in oncology? JK The risk/benefit ratio is an important concern. When treating […]
The August issue is now available on our site
H&O Which patients with melanoma are at elevated risk for a recurrence after surgical resection? JW A patient at elevated risk is one whose 5-year […]
The July issue of Clinical Advances in Hematology & Oncology is available on our website
H&O What treatments are available for patients with sickle cell disease? KA Sickle cell disease (SCD) can be cured with allogeneic hematopoietic stem cell transplant. […]
See the articles from our newest (June) issue
H&O What is bipolar androgen therapy (BAT)? SD BAT consists of the administration of a high dose of androgen—also called testosterone—in an effort to control […]
The April issue is now available on our website -- check it out!
H&O Which patients with AML are at higher risk for relapse? CD Unfortunately, most adult patients with acute myeloid leukemia (AML) will relapse. Features associated […]
Be sure to read the March issue of Clinical Advances in Hematology & Oncology, now on our website
H&O How common is thrombosis in patients being treated for cancer? MS Approximately 20% to 25% of patients with venous thromboembolism (VTE) at a typical […]
Check out the February issue of Clinical Advances in Hematology & Oncology, which is now on our website
H&O What is considered the standard adjuvant treatment for stage III BRAF-mutated melanoma? GL The standard treatment for patients with stage III BRAF-mutated melanoma after […]
The January issue of Clinical Advances in Hematology & Oncology is available on our website. https://buff.ly/2s1L2Ri
H&O How common is chemotherapy-induced peripheral neuropathy? MS Chemotherapy-induced peripheral neuropathy (CIPN) is almost universal with certain neurotoxic drugs. Two types of therapies are classically […]
Be sure to check out the December issue of Clinical Advances in Hematology and Oncology on our website
H&O How common is chemotherapy-induced peripheral neuropathy? MS Chemotherapy-induced peripheral neuropathy (CIPN) is almost universal with certain neurotoxic drugs. Two types of therapies are classically […]
The November issue of Clinical Advances in Hematology & Oncology is on our site
H&O Which patients with colon cancer require adjuvant therapy? AS Patients who are considered to be at high risk for recurrence require adjuvant therapy. This […]
Letter from the Editor: How to treat Hodgkin lymphoma, by Brad S. Kahl, MD
Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Letter from the Editor: How to Treat Hodgkin Lymphoma Brad S. Kahl, MD Download PDF Last weekend, I attended the 2017 ASH Meeting on Hematologic Malignancies. This is an incredible 2-day meeting organized around a series...
Encorafenib and binimetinib in BRAF-mutated melanoma, with Keith Flaherty, MD
Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 In the Pipeline: Encorafenib and Binimetinib in BRAF-Mutated Melanoma Keith Flaherty, MD Professor of Medicine Harvard Medical School Boston, Massachusetts Download PDF H&O What makes the BRAF inhibitor encorafenib plus…
Genomics in advanced prostate cancer, with Maha H. Hussain, MD
Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 The Role of Genomics in Patients With Advanced Prostate Cancer Maha H. Hussain, MD Genevieve E. Teuton Professor of Medicine Deputy Director Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago, Illi...
When to initiate treatment in smoldering multiple myeloma, with María-Victoria Mateos, MD
Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 When to Initiate Treatment in Smoldering Multiple Myeloma María-Victoria Mateos, MD, PhD Director of the Myeloma Unit Haematology Department University Hospital of Salamanca Salamanca, Spain Download PDF H&O How is smold...
DNA repair gene mutations in advanced prostate cancer, by Emmanuel S. Antonarakis, MD
Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Prognostic and Therapeutic Implications of DNA Repair Gene Mutations in Advanced Prostate Cancer Michael T. Schweizer, MD, and Emmanuel S. Antonarakis, MD Dr Schweizer is an assistant professor in the Division of Oncology…
Direct-to-consumer advertising of cancer treatments, with Lowell E. Schnipper, MD
http://www.hematologyandoncology.net/archives/october-2017/direct-to-consumer-advertising-of-cancer-treatments/
Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Direct-to-Consumer Advertising of Cancer Treatments Lowell E. Schnipper, MD Theodore and Evelyn Berenson Distinguished Professor of Medicine in the Field of Oncology Harvard Medical School Clinical Director, Cancer Center…
The management of essential thrombocythemia, by Laura C. Michaelis, MD
Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Current Challenges in the Management of Essential Thrombocythemia Ariel Kleman, MD, Arun K. Singavi, MD, and Laura C. Michaelis, MD Corresponding author: Laura C. Michaelis, MD Hematology and Oncology Medical College of Wi...
New approvals for tisagenlecleucel (Kymriah, Novartis) and notuzumab ozogamicin (Besponsa, Pfizer), and reapproval for gemtuzumab ozogamicin (Mylotarg, Pfizer)
Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Hem/Onc News Devon Schuyler Download PDF First Gene Therapy Approved for Use in Acute Lymphoblastic Leukemia The US Food and Drug Administration (FDA) has approved tisagenlecleucel (Kymriah, Novartis), the first chimeric a...
The optimal duration of adjuvant therapy in colon cancer, with Anthony F. Shields, MD, PhD
Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 What Is the Optimal Duration of Adjuvant Therapy in Colon Cancer? Anthony F. Shields, MD, PhD Professor of Medicine and Oncology Associate Center Director for Clinical Sciences Karmanos Cancer Institute, Wayne State Univer...
How I treat stage IV non–small cell lung cancer in the absence of any actionable oncogenic driver, by Mark A. Socinski, MD
http://www.hematologyandoncology.net/archives/october-2017/how-i-treat-stage-iv-non-small-cell-lung-cancer-in-the-absence-of-any-actionable-oncogenic-driver/
Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 How I Treat Stage IV Non–Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Download PDF Overview • T...
The October issue of Clinical Advances in Hematology & Oncology is now available
H&O Which patients with colon cancer require adjuvant therapy? AS Patients who are considered to be at high risk for recurrence require adjuvant therapy. This […]
Letter From the Editor: The Panama Canal, by Brad S. Kahl, MD
Clinical Advances in Hematology & Oncology September 2017 - Volume 15, Issue 9 Letter From the Editor: Book Club: The Panama Canal Brad S. Kahl, MD Download PDF I don’t know how people in our profession find time to read for pleasure. A stack of medical material is always awaiting my attention. Unti...
Radium-223 in patients with metastatic castration-resistant prostate cancer, with Daniel J. George, MD
Clinical Advances in Hematology & Oncology September 2017 - Volume 15, Issue 9 Optimal Use of Radium-223 in Patients With Metastatic Castration-Resistant Prostate Cancer Daniel J. George, MD Professor of Medicine and Surgery Divisions of Medical Oncology and Urology Duke University Medical Center Du...
Highlights in kidney cancer from the 2017 American Society of Clinical Oncology Annual Meeting
Clinical Advances in Hematology & Oncology September 2017 - Volume 15, Issue 9 Highlights in Kidney Cancer From the 2017 American Society of Clinical Oncology Annual Meeting Download PDF 1From the 2017 American Society of Clinical Oncology Annual Meeting June 2-6, 2017 • Chicago, Illinois Adjuvant P...
The value in cancer care consortium: addressing financial toxicity, with Allen S. Lichter, MD, Value in Cancer Care Consortium
Clinical Advances in Hematology & Oncology September 2017 - Volume 15, Issue 9 The Value in Cancer Care Consortium: Addressing Financial Toxicity Allen S. Lichter, MD Chairman Value in Cancer Care Consortium Ann Arbor, Michigan Download PDF H&O What is the Value in Cancer Care Consortium? AL The V...
Testicular seminoma: oncologic rationale and role of surgery in treatment, by Andrew J. Stephenson, MD
Clinical Advances in Hematology & Oncology September 2017 - Volume 15, Issue 7 Testicular Seminoma: Oncologic Rationale and Role of Surgery in Treatment Nitin K. Yerram, MD, Hans C. Arora, MD, Abhinav Khanna, MD, Kyle Ericson, MD, Andrew Y. Sun, MD, Paurush Babbar, MD, Naveen Nandanan, MD, and Andre...
Polycythemia Vera: a review by Francesco Passamonti, MD
Clinical Advances in Hematology & Oncology September 2017 - Volume 15, Issue 9 Polycythemia Vera: From New, Modified Diagnostic Criteria to New Therapeutic Approaches Margherita Maffioli, MD, Barbara Mora, MD, and Francesco Passamonti, MD Drs Maffioli and Mora are hematologists in the hematology dep...
Primary central nervous system lymphoma with Kieron Dunleavy, MD
Clinical Advances in Hematology & Oncology September 2017 - Volume 15, Issue 9 Advances in the Management of Primary Central Nervous System Lymphoma Kieron Dunleavy, MD Professor of Medicine George Washington University Director of Lymphoma GW Cancer Center Washington, DC Download PDF H&O What is…
Treatment of platinum-sensitive recurrent ovarian cancer with Bradley J. Monk, MD
Clinical Advances in Hematology & Oncology September 2017 - Volume 15, Issue 9 Optimal Treatment for Platinum-Sensitive Recurrent Ovarian Cancer Bradley J. Monk, MD Professor of Gynecologic Oncology University of Arizona and Creighton University Phoenix, Arizona Download PDF H&O How common is ovar...
The September issue of Clinical Advances in Hematology & Oncology is available on our website.
H&O How common is ovarian cancer? BJM The American Cancer Society estimates that ovarian cancer will be diagnosed in 22,440 women and that 14,080 women […]
Highlights in breast cancer from the ASCO meeting, with commentary by Dr Hope S. Rugo
Clinical Advances in Hematology & Oncology August 2017 - Volume 15, Issue 8 Highlights in Breast Cancer From the 2017 American Society of Clinical Oncology Annual Meeting Commentary by Hope S. Rugo, MD Download PDF June 2-6, 2017 • Chicago, Illinois Subset of Patients With Heavily Pretreated Metas...
Emerging treatments in acute myeloid leukemia by Dr Elihu Estey
Clinical Advances in Hematology & Oncology August 2017 - Volume 15, Issue 8 Emerging Treatments in Acute Myeloid Leukemia: Current Standards and Unmet Challenges Mary-Elizabeth Percival, MD, MS, and Elihu Estey, MD Dr Percival is an assistant professor and Dr Estey is a professor in the division of…
New treatments for stage I testicular cancer by Christian K. Kollmannsberger, MD
Clinical Advances in Hematology & Oncology August 2017 - Volume 15, Issue 8 New Treatments for Stage I Testicular Cancer Lucia Nappi, MD, PhD, Craig R. Nichols, MD, and Christian K. Kollmannsberger, MD Dr Nappi is a medical oncology fellow with the British Columbia Cancer Agency at the Vancouver Can...
Letter From the Editor by Brad S. Kahl, MD: Take Back the Research
Clinical Advances in Hematology & Oncology August 2017 - Volume 15, Issue 8 Letter From the Editor: Take Back the Research Brad S. Kahl, MD Download PDF If you do not read the Editor’s Corner by Mikkael Sekeres in ASH Clinical News, you should. It is a good read. Mikkael’s piece in the June 2017 iss...
Synergizing radiation therapy and immune checkpoint blockade in non–small cell lung cancer, by David S. Ettinger, MD
Clinical Advances in Hematology & Oncology August 2017 - Volume 15, Issue 8 The Next Frontier in Non–Small Cell Lung Cancer: Synergizing Radiation Therapy and Immune Checkpoint Blockade Khinh Ranh Voong, MD, MPH, Jarushka Naidoo, MBBCh, and David S. Ettinger, MD, FACP, FCCP The authors are affiliate...
611 Broadway, Rm 310
New York, NY
10012
| Monday | 09:00 - 17:00 |
| Tuesday | 09:00 - 17:00 |
| Wednesday | 09:00 - 17:00 |
| Thursday | 09:00 - 17:00 |
| Friday | 09:00 - 17:00 |
| Saturday | 09:00 - 17:00 |
| Sunday | 09:00 - 17:00 |
Be the first to know and let us send you an email when Clinical Advances in Hematology & Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Send a message to Clinical Advances in Hematology & Oncology:
Light and Shadow: Digital Filmmaking Workshop
632 Broadway, Ste 304
